Skip to main content
About
Contact
Subscribe
e-Edition
Make Home Page
Sign Up
Log In
Dashboard
Logout
My Account
Dashboard
Profile
Saved items
Logout
Facebook
Twitter
Toggle navigation
Site search
Search
Home
Contact Us
Advertise
Subscription Services
Promote Your Event
Submission Forms
News
Local News
National
World
Archives
Sports
Local Sports
National Sports
Business
Local Business
National Business
Technology
Markets & Stocks
Opinion
Columns
Editorials
Letters To The Editor
Polls
Thumbs
A & E
Local Entertainment
Art Scene
Music Scene
Theatre Scene
Book Reviews
Movie Reviews
TV Listings
Local Events
What To Do
Life
Health
Travel
Oddities
Community Directory
Community Service
Rescue Me
Other
Magazines
Fall Home Improvements
Women
Home & Realty
Outdoor Guide
Premier Home Style Tour 2024
Spring Home & Garden Show
Spring on the Road
Spring Wellness
Classifieds
Place Ad
Careers
Tenders
Weather
Obituaries
Parcel Pickup
2024 Readersâ Choice
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Century Therapeutics Inc
(NQ:
IPSC
)
1.480
-0.070 (-4.52%)
Streaming Delayed Price
Updated: 10:22 AM EST, Dec 4, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Century Therapeutics Inc
< Previous
1
2
3
4
Next >
Century Therapeutics to Host Conference Call to Discuss Preliminary Clinical Data from Phase 1 ELiPSE-1 trial of CNTY-101 in Relapsed or Refractory B-cell Lymphomas and Planned Phase 1 Study in Systemic Lupus Erythematosus
December 06, 2023
From
Century Therapeutics, Inc.
Via
GlobeNewswire
Century Therapeutics Receives FDA Clearance of IND Application for CNTY-101 in Systemic Lupus Erythematosus
December 06, 2023
From
Century Therapeutics, Inc.
Via
GlobeNewswire
Penny Stock Jackpots: 3 High-Stakes Picks With 10-Bagger Potential
December 05, 2023
Although speculative ideas tend to be losers more so than winners, these 10-bagger penny stocks might tempt the gambler.
Via
InvestorPlace
Recap: Century Therapeutics Q3 Earnings
November 09, 2023
Via
Benzinga
Century Therapeutics: Q1 Earnings Insights
May 11, 2023
Via
Benzinga
Analyst Ratings for Century Therapeutics
April 13, 2023
Via
Benzinga
Century Therapeutics's Return On Capital Employed Overview
March 20, 2023
Via
Benzinga
Harnessing The Power Of Gamma-Delta T Cells In Cancer Therapy: IN8bio's Innovative Approach
November 27, 2023
Why Are Gamma-Delta T Cells Important In Fighting Cancer?
Via
Benzinga
Century Therapeutics to Present at the Piper Sandler 35th Annual Healthcare Conference
November 21, 2023
From
Century Therapeutics, Inc.
Via
GlobeNewswire
Century Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business Updates
November 09, 2023
From
Century Therapeutics, Inc.
Via
GlobeNewswire
Century Therapeutics and FUJIFILM Cellular Dynamics Announce Licenses for the Development and Commercialization of iPSC-Derived Cell Therapies in Autoimmune and Inflammatory Diseases
November 09, 2023
From
Century Therapeutics, Inc.
Via
GlobeNewswire
Where Century Therapeutics Stands With Analysts
March 16, 2023
Via
Benzinga
Century Therapeutics Appoints Brent Pfeiffenberger, Pharm.D., MBA, as Chief Executive Officer
November 09, 2023
From
Century Therapeutics, Inc.
Via
GlobeNewswire
Century Therapeutics to Present Initial Clinical Data Supporting the Potential for a Multi-Dosing Strategy for CAR iNK Enabled by Allo-Evasion™ Edits at the 65th ASH Annual Meeting and Exposition
November 02, 2023
From
Century Therapeutics, Inc.
Via
GlobeNewswire
Century Therapeutics to Present at the Chardan 7th Annual Genetic Medicines Conference
September 26, 2023
From
Century Therapeutics, Inc.
Via
GlobeNewswire
Benzinga's Top Ratings Upgrades, Downgrades For August 28, 2023
August 28, 2023
Via
Benzinga
Workday To Rally Around 20%? Here Are 10 Other Analyst Forecasts For Monday
August 28, 2023
Truist Securities raised the price target for Church & Dwight Co., Inc. (NYSE: CHD) from $95 to $105. Truist Securities analyst Bill Chappell upgraded the stock from Hold to Buy. Church & Dwight shares...
Via
Benzinga
These Analysts Slash Their Forecasts On Century Therapeutics After Weak Q2 Results
August 10, 2023
Century Therapeutics, Inc. (NASDAQ: IPSC) reported weaker-than-expected second-quarter results.
Via
Benzinga
Century Therapeutics Reports Second Quarter 2023 Financial Results and Provides Business Updates
August 09, 2023
From
Century Therapeutics, Inc.
Via
GlobeNewswire
Century Therapeutics Reports First Quarter 2023 Financial Results and Provides Business Updates
May 11, 2023
From
Century Therapeutics, Inc.
Via
GlobeNewswire
Century Therapeutics to Present at Chardan’s 7th Annual Genetic Medicines & Cell Therapy Manufacturing Virtual Summit
April 17, 2023
From
Century Therapeutics, Inc.
Via
GlobeNewswire
Century Therapeutics Announces Leadership Changes
April 12, 2023
From
Century Therapeutics, Inc.
Via
GlobeNewswire
Century Therapeutics Reports Full Year 2022 Financial Results and Provides Business Updates
March 16, 2023
From
Century Therapeutics, Inc.
Via
GlobeNewswire
Century Therapeutics to Present at the AACR Annual Meeting 2023
March 15, 2023
From
Century Therapeutics, Inc.
Via
GlobeNewswire
Century Therapeutics to Present at Upcoming Investor Conferences
February 21, 2023
From
Century Therapeutics, Inc.
Via
GlobeNewswire
Century Therapeutics Announces First Patient Dosed in First-In-Human Phase 1 ELiPSE-1 Trial Evaluating CNTY-101 in Relapsed or Refractory CD19 Positive B-cell Lymphomas
February 08, 2023
From
Century Therapeutics, Inc.
Via
GlobeNewswire
Century Therapeutics to Present at Upcoming Investor Conferences
February 01, 2023
From
Century Therapeutics, Inc.
Via
GlobeNewswire
How Will Early 2023 Layoffs Affect These 5 Biotech Stocks?
January 25, 2023
Five biotechs have already issued layoffs in 2023. Many seem to have good potential, but time will tell if the shifts create the value analysts anticipate.
Via
MarketBeat
Topics
Workforce
Exposures
Layoff
Product Safety
Stocks That Hit 52-Week Lows On Thursday
January 19, 2023
On Thursday, 29 stocks made new 52-week lows.
Via
Benzinga
5 Health Care Stocks That Are Diving - And May Rally
January 19, 2023
The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies.
Via
Benzinga
< Previous
1
2
3
4
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.